![](/images/attention_icon.gif)
Expired activity
Please go to the PowerPak
homepage and select a course.
Polypharmacy refers to the practice of taking multiple medications. There is more to the concept of polypharmacy than just the actual number of prescriptions taken, however. Many potential problems can arise when certain medications are combined with each other, and when prescriptions are added to treat side effects caused by other drugs. Not surprisingly, the chances of polypharmacy increase as the patient ages, as do the chances for complications and medication–related problems to occur.
It’s important to recognize that many complex health conditions require a variety of prescribed and over–the–counter (OTC) medications for effective treatment. The term polypharmacy implies the need to work on or manage potential medication problems that often accompany the use of multiple medications by patients who live with comorbid medical conditions. During a comprehensive MTM process, the pharmacist can look at the whole medication regimen together, to identify how the medications might interact with each other and affect the individual. Alternatively, the pharmacist can perform a focused MTM where the goal is to work on specific problems. This may include problems with a particular medication, or the patient’s ability to monitor a medication’s effectiveness (i.e., blood pressure control). Through MTM, the pharmacist can work together with medical professionals and the patient to identify which medications are necessary and how to reduce the chances that use of multiple medications may cause harm.
WHAT IS POLYPHARMACY?
Polypharmacy is defined as “the concurrent use of multiple medications.”1 Some definitions consider polypharmacy to be five or more drugs, but other definitions do not specify a number.
Data from the Agency for Healthcare Research & Quality (AHRQ) showed that in 2006 the average adult used at least four unique prescriptions. Senior citizens (over age 65) used approximately six different prescriptions per person. Some recent data on prescription drug use in the United States are summarized Figure 1.1 Among adults age 60 and older, 84% had filled at least one prescription in the past 30 days and 35% had filled five or more.1
Figure 1. Use of 1 or More or 5 or More Prescriptions in Past 30 Days1
U.S. and Canadian Adults aged 40–79, by age group (2015–2016 U.S.) |
![](/courses/120610/fig1.jpg) |
Source: National Center for Health Statistics (NCHS), National Health and Nutrition Examination Survey, 2015–2016, and Statistics Canada, Canadian Health Measures Survey, 2016–2017. |
The total number of prescriptions filled by each individual in a given year tells another part of the story. Kaiser Family Foundation data show that adults ages 19 to 64 filled an average of 11.6 prescriptions per person in 2019, depending upon the region (Figure 2).2 The Affordable Care Act (ACA, or Obamacare) provided healthcare access for many people who were previously uninsured, which may have increased the numbers of prescriptions.
Figure 2. Average Number of Prescriptions Filled in 2019 Per Adult (age 19 to 64)2 |
![](/courses/120610/fig2.jpg) |
Source: Kaiser Family Foundation. Retail Prescription Drugs Filled at Pharmacies (Annual Per Capita). 2019.2 |
WHY IS POLYPHARMACY INCREASING?
A number of healthcare and societal factors are driving the trend toward increased prescribing of medications. Some of these factors are outlined below:3-5
![](/courses/120610/chart1.jpg)
Unintentional causes of polypharmacy. In some cases, a prescribing physician is not fully aware of how many drugs a patient may be taking. This frequently occurs when a patient sees multiple physicians and fails to give a full medication history, either because the patient can’t remember the drugs, chooses not to report them, or lacks the ability to convey this information due to cognitive problems, language barriers, etc. Some of the other issues driving polypharmacy include the “prescribing cascade.” Usually, this term refers to the situation in which medications are used to treat the side effects of other medications—that is, using one drug to treat a problem with another drug (Figure 3).3
Figure 3. The Prescribing Cascade3
The Prescribing Cascade |
![](/courses/120610/fig3.jpg) |
An example might be when a chemotherapy drug causes nausea, a medication is added to treat the nausea, but this agent causes headaches, so the patient uses an over–the–counter medication to treat headache. In some cases, the drug side effect is mistaken for a new diagnosis and the problem of polypharmacy escalates, as outlined in Figure 4.
![](/courses/120610/fig4.jpg) |
Figure 4. In this example of the prescribing cascade, a patient is treated for arthritis with high doses of a nonsteroidal anti-inflammatory drug (NSAID). These agents are known to be associated with hypertension. However, in her case the hypertension is seen as a new condition, so a calcium channel blocker (CCB) is prescribed. When ankle swelling develops, a diuretic is added to the regimen to help clear fluids. Diuretic use can increase the risk of gout, especially in patients who already susceptible due to arthritis. When allopurinol is prescribed, the patient's condition deteriorates further. Source: Demetra Antimisiaris, PharmD. |
Transitions of care. Polypharmacy often starts or increases during transitions of care.5 A patient may be discharged from the hospital with a different set of medications than those prescribed by the primary care physician, even if the underlying health problem did not change. The patient now has a new set of prescriptions from the hospital, and may have leftover medications at home that he or she is not sure how to fit in with the newly prescribed ones. Despite better efforts toward reconciling medication lists during care transitions in some facilities, polypharmacy often goes unrecognized and can lead to patient harm.5-7
Drug advertising, and the pressure to prescribe. Few people would question that consumer advertising has driven the demand for prescription drugs in recent decades. Consumer advertising of pharmaceuticals continues to be successful in stimulating consumer demand for prescription drugs, especially as a greater variety of medications becomes available. Research shows that patients do initiate discussions with their doctors about advertised medications and ask for the products by name, as the ads intended.8 In a survey of 500 physicians conducted by the FDA in 2004 revealed that most doctors believe that consumer drug advertising affects their interaction with patients: 73% of PCPs and 63% of specialists said they thought patients came to the appointment expecting a prescription.9
WHAT ARE SOME PROBLEMS ASSOCIATED WITH POLYPHARMACY?
Some of the common problems that occur with polypharmacy include an increased risk of drug-drug interactions, higher chances of experiencing drug side effects, and toxic effects due to long-term drug treatment.10 Other problems relate to how patients take the medication. Studies show that greater numbers of prescriptions and higher “pill counts” are associated with higher degrees of nonadherence. In addition, patients who take multiple medications are more likely to make mistakes between the agents and inadvertently take doses incorrectly as a result (e.g., mixing up two different-sized blue pills). Some of these problems have the potential to cause immediate harm, such as an overdose. However, in many cases, drug side effects are subtle and slow to evolve. They may be difficult to distinguish from “normal” aches and pains, or from the effects of the medical condition being treated. Some of the most common adverse effects that occur with medications are listed below:
![](/courses/120610/chart2.jpg)
The high economic costs of polypharmacy are also important to consider—even when relatively inexpensive medications are used, the cost of copayments and out–of–pocket expenses adds up when multiple chronic medications are used. Just one high–priced medication can put patients over the edge, or exceed their insurance plan’s allowance for drug spending. The effects of polypharmacy on an individual cannot always be predicted. Some patients are able to tolerate multiple medication regimens well, while others experience problems. This is due to individual differences in how people respond to drug treatment (Figure 5).
Figure 5. Definitions of Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics
![](/courses/120610/fig5.jpg)
Pharmacodynamic and pharmacokinetic issues do not stay the same, but change throughout life. Pharmacogenomics is based on a person’s genetic makeup. Some aspects are set at birth, but diseases, medications, and the environment interact with genetic set points to evoke changes. (For example, people who are slow metabolizers can take drugs that induce them to be fast metabolizers). Pharmacokinetics and pharmacodynamics change as a person ages and affect drug absorption and risk of side effects.11 Polypharmacy is particularly a concern in older adults—this issue is discussed in detail in Module 8. Medication Use Among Older Adults.
Unfortunately, most pharmaceutical clinical trials do not provide a good overview of how a broad population of patients is going to respond to the drug.12 Initial safety studies are conducted in healthy volunteers.13 Most clinical trials for medications have a long list of “exclusion criteria”—people who do not qualify to enroll in the trial. Looking at these lists, you will see that the segment of the population in which the drug was studied does not often reflect the population using it: they may be older, have multiple medical problems, and take multiple medications.
Drug trials look at the effects in terms of a sample population as a whole, and are not actually designed to assess the effects in any given individual. People can respond very differently to medications. This is one of the reasons why MTM is so important. MTM does exactly what drug trials do not, which is to examine the effects of drug treatments on an individual, to assess each medication individually, and how they might interact when multiple medications are used.
MTM: HOW PHARMACISTS, TECHNICIANS, AND HEALTHCARE PROVIDERS CAN PREVENT AND ADDRESS POLYPHARMACY
As noted above, MTM is tailored to address the issue of polypharmacy. During an MTM session, pharmacists trained in these methods can:
- Evaluate whether all the medications a person is taking are necessary: Are they effective? Safe, and/or do the benefits outweigh possible safety risks?
- Evaluate how the medications affect the person’s well–being and quality of life
- Explore ways to reduce costs of the medications (prescription and OTC)
- Determine whether certain medications can be discontinued, changed, substituted, or have a different dosage or administration method
Table 2. Prescribing Checklist to Prevent Unnecessary Polypharmacy |
Indication · Is the medication appropriate for this patient? · Does each medication on the list have an appropriate indication? |
Effectiveness · Are treatment goals being met? · Is the medication the most effective available? |
Safety · Is the dose appropriate for the patient? · Are there long-term risks associated with the drug? · Does the patient have signs of adverse drug effects or interactions? |
Adherence · Will the patient be able to follow directions for use and remember to take? · Are there barriers that could prevent the patient from using the drug correctly? (e.g., difficulty handling the container or administering the medication; visual impairment) · Is the cost of the medication a factor in the patient’s adherence? |
Technicians involved in MTM services should understand why polypharmacy is a concern, and the goals of MTM in relation to reducing the potential risks of polypharmacy. Technicians may be involved in developing a Personal Medication List (PML) and may recognize some of the possible warning signs of polypharmacy to alert the pharmacist (e.g., when certain high–risk drugs are being used together). Technicians may have a role in reminding patients to follow through with monitoring steps (for example, blood tests) to identify adverse effects of medications. Technicians who have high levels of interaction with patients or medical/nursing staff (i.e., in hospitals) are in a unique position to gather information about commonly overlooked factors, such as hidden supplement use, or patient refusal to take a medication.
CHALLENGES IN MANAGING POLYPHARMACY
Problems associated with polypharmacy are not always easy to detect and may also be frustrating to overcome. A number of challenges may arise when the pharmacist and technician team attempt to address issues in polypharmacy:
![](/courses/120610/chart3.jpg)
When the MTM session does not yield a clear sense of what the patient is taking, the pharmacist conducting MTM may ask the patient to conduct an at-home “medication administration record” for a certain time period, usually about 30 days. During this time, patients are asked to record:
- What they have taken
- When (what times) they are taking it
- Any missed doses that occur
- Effects they notice while taking the drug (efficacy, possible side effects)
- Issues in daily living that may be related: diet, sleep patterns, etc.
How a patient takes a drug is an important issue and may provide important clues to how the drugs work for them and whether side effects occur. Some examples include:
- Taking certain medications (such as the thyroid medication levothyroxine) along with foods or other drugs can interfere with how the drug is absorbed in the body. Patients may not get the benefits of the drug as intended.
- Other medications should be taken with food to reduce possible gastrointestinal upset. A number of common antibiotics fall into this category.
- Is the person crushing a tablet that is not meant to be crushed, or opening up a capsule to “sprinkle” over food instead of swallowing it whole? While it may seem obvious that people should avoid “breaking the rules” when taking their medications, most
- consumers do not recognize how a sustained–release tablet works and that the way it is swallowed affects whether the drug is released into the body as intended.
- Drug allergies are another possible source of confusion. Consumers may not recognize classic signs of actual drug allergy (rash, hives, chest tightness or difficulty breathing). They may assume they are “allergic” to a drug if it caused them to vomit at some point, or caused headaches.
CONCLUSION
Polypharmacy cannot always be avoided. Certain complex disease states—such as diabetes, cancers, cardiovascular diseases—require a number of medications to control the disease and to minimize its effects on the individual. A person who has had a stroke or heart attack is usually prescribed several medications to reduce the risk of mortality or another catastrophic event. In this sense, polypharmacy is not necessarily the enemy. But, patients who take multiple medications can always benefit from a careful review and individual assessment of whether they are safe, necessary, effective, cost–effective, and taken properly.
REFERENCES
- National Center for Health Statistics (NCHS), National Health and Nutrition Examination Survey, 2015–2016, and Statistics Canada, Canadian Health Measures Survey, 2016–2017. Available at: https://www.cdc.gov/nchs/images/databriefs/301-350/db347_fig3.png.
- Kaiser Family Foundation. State Health Facts. Retail Prescription Drugs Filled at Pharmacies per Capita. Timeframe 2019. Available at: https://www.kff.org/state-category/health-costs-budgets/prescription-drugs/.
- Antimisiaris D, Cheek DJ. Polypharmacy. In: Mauk KL. Gerontological Nursing. Burlington, MA: Jones & Bartlett. 2014:417-456.
- Gamble JM, Hall JJ, Marrie TJ, et al. Medication transitions and polypharmacy in older adults following acute care. Ther Clin Risk Manag. 2014;10:189-196.
- Patterson SM, Cadogan CA, Kerse N, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2014(10):Cd008165.
- Tamura BK, Bell CL, Inaba M, et al. Outcomes of polypharmacy in nursing home residents. Clin Geriatr Med. 2012;28(2):217-236.
- Kojima G, Bell C, Tamura B, et al. Reducing cost by reducing polypharmacy: the polypharmacy outcomes project. J Am Med Dir Assoc. 2012;13(9):818.e811-815.
- Gellad ZF, Lyles KW. Direct-to-consumer advertising of pharmaceuticals. Am J Med. 2007;120(6):475-480.
- Aikin KJ, Swasy JL, Braman AC. Executive Summary. U.S. Department of Health and Human Services, Food & Drug Administration; Center for Drug Evaluation and Research; 2004. Patient and Physician Attitudes and Behaviors Associated with DTC Promotion of Prescription Drugs – Summary of FDA Survey Research Results. Available at: http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/DrugMarketingAdvertisingandCommunicationsResearch/UCM152890.pdf.
- Tannenbaum C, Sheehan NL. Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol. 2014;7(4):533-544.
- Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65.
- Niederseer D, Thaler CW, Niederseer M, et al. Mismatch between heart failure patients in clinical trials and the real world. Int J Cardiol. 2013;168(3):1859-1865.
- Magid DJ, Estabrooks PA, Brand DW, et al. Advances in Patient Safety: Translating Patient Safety Research into Clinical Practice. In: Henriksen K, Battles JB, Marks ES, et al., eds. Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005.